NurExone Biologic Inc. Reports Financial Performance for the Fiscal Year
Tuesday, 2 April 2024, 14:43
NurExone Biologic Inc. Reports Fiscal Year Results
NurExone Biologic Inc. recently disclosed its financial performance for the fiscal year, revealing a net loss of US$3.64 million. The company's research and development expenses were recorded at US$1.54 million.
Key Highlights:
- Cash Balance: NurExone Biologic disclosed details about its cash balance.
This comprehensive report provides valuable insights into NurExone Biologic’s financial status and performance.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.